Xiaokun Xiao

Ionis Pharmaceuticals (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index1.8kcitations40works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA and Nucleic Acid Chemistry(20), Microtubule and mitosis dynamics(15), Genetics, Bioinformatics, and Biomedical Research(10), Monoclonal and Polyclonal Antibodies Research(8), CRISPR and Genetic Engineering(4)

Publications40 total

Supplementary Figure 4a from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 3a from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 3d from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 1a and 1b from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 2b from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Data from Selective Down-Regulation of Glioma-Associated Oncogene 2 Inhibits the Proliferation of Hepatocellular Carcinoma Cells
2023Open Access
Supplementary Figure 4b from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 3c from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Data from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Data from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Table 1 from Selective Down-Regulation of Glioma-Associated Oncogene 2 Inhibits the Proliferation of Hepatocellular Carcinoma Cells
2023Open Access
Supplementary Figure 3b from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure Legends from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 3a from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 2a from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 4a from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Data from Selective Down-Regulation of Glioma-Associated Oncogene 2 Inhibits the Proliferation of Hepatocellular Carcinoma Cells
2023Open Access
Supplementary Table 1 from Selective Down-Regulation of Glioma-Associated Oncogene 2 Inhibits the Proliferation of Hepatocellular Carcinoma Cells
2023Open Access
Supplementary Figure 2a from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 2b from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Nicholas M. Dean(28), Erich Koller(23), Stephanie Propp(23), MingYi Chang(23), Scott A. Hirsch(23), Peter J. Shepard(23), Seongjoon Koo(23), Cain Murphy(23), Robert I. Glazer(23), Chenguang Zhao(21), Brett P. Monia(11), Hong Zhang(8), Gene Hung(6), Youngsoo Kim(6), Tianyuan Zhou(6), A. Robert MacLeod(6), Joanna Schmidt(5), Jeff Hsu(5), Joon Won Yoon(5), Eric G. Marcusson(5)